The news: An FDA advisory committee recommended Grail’s Galleri multi-cancer early detection blood test for approval, voting 7-2 (with one abstention) that its benefits outweigh its risks.

Digging deeper: Whether the test is actually effective remains the central question, as evidenced by the panel’s divided 6-4 vote on effectiveness compared with its unanimous 10-0 verdict on safety.

This divide stems from lingering questions about Galleri’s clinical benefit: while adding the test to standard screening increased cancer detection fourfold, it missed its primary endpoint in a UK NHS trial by failing to significantly reduce combined stage III and IV diagnoses. High false-positive rates—with one-third to half of positive results turning out to be false, per STAT—further fueled panel skepticism ahead of the FDA's upcoming approval decision.

Why it matters: Consumer demand for multi-cancer blood testing is already high without insurance coverage—but the recommendation will move it closer to broader insurance coverage, increasing affordability and accessibility. Even with a list price of $949 and lacking insurance coverage, Grail sold more than 185,000 Galleri tests in 2025, and more than 117,000 in H1 2026, up 42% YoY..

FDA approval would open a path to Medicare coverage. A law signed in February allows Medicare coverage for eligible FDA-approved multi-cancer early detection screening tests beginning in 2028, subject to CMS coverage determination.

Broader commercial coverage could be harder to secure given questions about false positives and clinical benefit. Private insurers follow a separate path, with coverage for preventive cancer screening generally tied to recommendations from the US Preventive Services Task Force.

Implications for healthcare systems and pharma companies: FDA approval would give Galleri more credibility with physicians who have been wary of a test marketed directly to consumers without the agency’s official backing. For example, some doctors have raised concerns about Galleri’s commercial marketing, including its appearance in Hims & Hers’ Super Bowl commercial, per STAT.

As consumer awareness grows, providers will face more questions about what Galleri results mean and how reliable they are. Health systems will need protocols for counseling patients and coordinating imaging, biopsies, specialist referrals, and other diagnostic workups after positive results. They’ll also need to reinforce the FDA’s proposed label to caution patients that negative results don’t rule out cancer or replace recommended screenings

For pharma companies, broader use of Galleri could bring more patients with harder-to-screen cancers into diagnostic and treatment pathways. An estimated 58% of US cancer deaths in 2026 will come from cancer types without recommended screening, per the FDA. For drugmakers in those areas that could create a need for earlier education around what pre-symptomatic positive results mean.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.